A new HBV cure treatment regimen for durable elimination of HBV cccdna in chronic HB infection

Hbvtech, LLC received a $4.73M Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2025 through June 30, 2029. The awardee, a minority-owned small disadvantaged business located in Germantown, Maryland, will develop and advance a novel hepatitis B virus (HBV) cure treatment regimen focused on the durable elimination of HBV covalently closed circular DNA (cccDNA) in chronic HBV infection. This research represents a continuation of the company's specialized work in antiviral drug development and gene therapy approaches for addressing chronic HBV infections.

Under this award, Hbvtech will leverage advanced molecular biology and gene therapy techniques to create innovative therapeutic interventions aimed at transforming chronic HBV infection treatment. The research activities are designed to explore mechanisms for eliminating HBV cccDNA, develop gene therapy strategies that may establish sustained immune responses against HBV reinfection, and ultimately provide a potential cure for chronic HBV infections. This work aligns with the Defense Health Agency's mission to support biomedical research that transforms healthcare for Service Members and the American public through hypothesis-driven research and novel therapeutic development.